In Asian patients with diabetes, baseline BMI subgroups showed no significant differences across reported lixisenatide treatment effects (interaction P >0.15).
In plain wordsIn Asian patients with diabetes, baseline BMI groups had similar reported treatment responses to lixisenatide.
- Peptide
- Lixisenatide
- Outcome
- No significant changeTreatment response by baseline BMI
- Study
n = 555
- Comparator
- Other baseline BMI subgroups
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- Dose not stated
Measurements
- P for interaction
- > 0.15
- BMI subgroups, listed outcomes
Source sentences
No significant differences in treatment effect between the BMI subgroups were observed for the changes from baseline to 24 weeks in glycated hemoglobin (HbA1c), fasting plasma glucose, postprandial glucose (PPG), PPG excursion, body weight, BMI, and basal insulin dose with lixisenatide,
3 context sentences(design, population, supporting numbers)
as well as the change in basal insulin dose at study endpoint and the proportion of participants achieving an HbA1c 0.15).
This analysis aims to investigate the efficacy and safety of once-daily lixisenatide add-on treatment to basal insulin in Asian individuals with type 2 diabetes, by baseline body mass index (BMI).
Efficacy and safety of lixisenatide versus placebo were evaluated among BMI subgroups.